Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yes, the initial FDA approval for clinical trials (if it comes) won't sustain the price by itself and funding is an issue to consider.
What we should be able to assess over the next 3-5 weeks is how much the company has or has not grown as a viable "business". Cavens has a tough job to raise funds for a company 3 years into an IND without approval. That's why Koos cut the deal with "Angel" investors - the only point of disagreement there is the price point he established for them was a slap in the face to every person who actually bought the stock over the market.
If CRL testing results (audited due early next week) are positive, IND should be approved at which point Cavens will have something to hawk without selling out the company. With approved IND in hand, Orphan Drug Status a follow up check mark and 3 more prospective drugs in the pipeline, some associated with outside (Dr. Kesari) reputable names, it should be a lot easier to find willing investors or buyers of new stock without selling out the company.
Will it happen? I have no idea, but until that type of normal business scenario unfolds, the reality sadly is, the PPS will struggle and be victim to the whims of anyone with a large enough following to pump, dump or disregard.
I'm certainly open to learning new things and new perspectives. Can you explain how short covering (needing to buy shares) would drive the PPS down instead of up?
I too do not think or see "dilutions" as an issue. As was pointed out by the O/S numbers, less than 1M shares added since end of June.
New4This, I don't see this as related to RGBP at all. RGBP has never talked about using Rabbit ATG.
While yesterday's trading action for the most part was very encouraging, can't say I can read anything positive into today's. With PR stating CRL report was due in full audited form on the 16th, the higher volume negative selling today is not a good sign.
There always a certain number of people that know the news ahead of time and I would expect the positive results we are hoping for would be pushing this higher on big volume or holding steady on low volume. Selling off on higher volume is an ominous sign that does not give me a good feeling today.
Hello? How does Volume show dilution? Oh, I see, shares of Microsoft and Apple must be diluted every day then because their volume is so much more than RGBP.
Hello? And then we pull up a year old PR on ebola for what, to somehow make a point that the HemaX studies won't be valid? Hello?
Only 2 trading days left to mid-Sept and 3 days to a Tuesday favorite PR day. Then we should see lots of one or the other, either a green day of over 50% gain up to 300% gain in my estimate or we see the share price drop on bad news down to .07.
I believe Dmort was referring to that figure once several products currently in the pipeline are approved. Certainly not in the next 30 days, but if RGBP had 3 cancer curing products approved by FDA, it would be even higher at that point.
We can speculate that once HemaX I is approved by FDA for clinical trials even, and Orphan Drug Status will come after as a formality, the exposure RGBP will get will skyrocket compared to now.
Then, RGBP's other product lines will get serious consideration such as dCellVax, Dr. Kesari's studies for glioma application of dCellVax IND expansion, the other BORIS studies etc. Once RGBP has one FDA approved clinical trial, then a lot of the past and past bashing will lose a leg to stand on and the company and its products as it is today will be the source of consideration more and more. Do not underestimate the esteem the Ichims have earned within the scientific community either.
Ah, that be a blest storm for sure if dCellVax come over the horizon and fill our sails as we head North. That be a treasure on top of treasure, like pearls on top of the gold coins we be diggin up!
Aaaaaarrrrrrrrrrrr!
Turn the sails about, ye laddies!!! The winds are a changin' and we be headin' North for a while!
Well, it be a dastardly crew that shorts before good news. They best have stolen an insider's knowledge if they be on the shorts, otherwise the first wave of buyin after positive news will capsize the boat and all treasure be lost. Arrrrggghhhhh
The question is was there any dilution in the past week? That is what was stickied. We are all aware, or everyone that reads a PR should be aware that shares have been issued for a variety of reasons over the course of 2015. It has been stated and listed in various filings by the company.
How many shares were issued last week?
"Mid-September" was the date to have the full audited report, but of course RGBP should already know the general results of the testing since you don't need the level of an audit to know the results in general.
We may get 4 periods of waves of buying: first on general news of the study data results if positive, the second upon PR relating the filing of the data with FDA for IND, the third upon FDA IND approval and the fourth shortly thereafter upon news of Orphan Drug Status. All this of course is contingent on our expectation that CRL study confirms the previous studies and data performed in house by BMSN/RGBP related scientists.
Boy, will it be nice if this happens and we can put the constant bashing of previous years mistakes to rest and open up to a new era for RGBP.
On the other hand, if the CRL studies for some reason do not confirm or are not sufficient, RGBP will be hit hard. Hoping for and my money is on the former. 2015 is the year of hope.
Sticky Post 17241 predicts dilution within a week and then goes into general market history.
Over a week has passed. If no dilution has occurred, this sticky should be taken down because it is deceptive and gives false info.
Sid,
1. "pathetic stock languishes..." It is closer to .20 or .10? hmmmm
2. "can't seem to understand how to submit a proper IND..." well, in the next 30 days or less most likely, either your statement will be proven completely false, or it will be confirmed.
We have a couple stickied notes that should either be verified or taken down it seems to me.
All's quiet and in another 45 minutes, only 3 trading days to mid-September and possible CRL report news!
Good morning and welcome back. Hopefully everyone got a little more time to relax with the extended weekend and no stocks to watch. Only 4 trading days left to mid-September.
Aaaaarrrrrrrrrrrrrggg! Jack, it's time to hoist the flag and reload the boat. Hoping for sunken treasures is running out and the time for the ship to sail from port is acomin' quick.
Step it up laddies. Time to gather the treasures in plain site and fill the coifers for the long trip ahead. The winds are arisin' and a storm is set to come in.
Don't want the mates to end up empty handed and thinking of mutiny!!!
Best be gathering up the supplies and gettin' all things in order to set sail mi laddy.
5 more trading days until "mid-September" completion of CRL testing with audited reports to be provided to RGBP. If the results are as positive as we expect, I would imagine some type of PR immediately about results with timeframe for filing the data with FDA.
Should that occur, things will certainly change around here for the better.
And the 10 Trading Day countdown to HemaX mid-Sept report news begins today! (And yes, also 1/6th of shares from convertible notes becoming free to trade began for some shares towards end of August and about 5M shares per month become free around Sept 24th, so that will also be a factor to consider with any rallies that will ensue over the coming months.)
But we are about to begin potentially the most exciting period of the past 3 years when we are not dependent on in house data, but will more and more be dependent on 3rd party experimental data based on in-house IP and research.
Recent PRs about future INDs will serve as background for new investors should the HemaX full study data give way to FDA approval to begin clinical trials, followed shortly thereafter by PR on Orphan Drug status and therefore quick development status.
If this is followed by Dr. Kesari aiding RGBP to file either a modified dCellVax IND or a new IND for glioma, Dr. Kesari's reputation and status at one of the few recognized NCRIs in the US will certainly give significantly more credence to RGBP as a viable company with valid IP than Koos ever could. And so the patterns of trading and PPS could substanitally change with just those 2 developments. Put on top of that that RGBP has announced the potential of several other INDs that could be initiated over the course of the upcoming year (remember that the Ichims incentive shares are based on 3 approved clinical trial products), and we will enter an entirely new and exciting phase for the company.
THE COUNTDOWN BEGINS!
Please keep comments to the company facts and development such as the hiring of full time scientists in Jan-Feb, multiple abstracts as well as oral presentations accepted at international scientific gatherings (did not happen before on any scale near 2015), new scientific board members who are specialists in the areas of RGBP product development, one new board member who is a head at one of the few nationally recognized Cancer Centers now working with RGBP to develop dCellVax for glioma as well as providing testing and data for general dCellVax IND approval, CRL (GLP) entity providing all the testing for the data to be submitted for HemaX IND approval to be completed within next 2 weeks (never happened before in company history to have such level of outside, independent lab expertise to move product line forward), several new patents and other IP purchased or filed in 2015.
I may have missed a few points, but hopefully those new to RGBP (following company less than one year) can get the idea from the facts that this is not "the same 'ol company" we've followed in the past.
Who said and where is documentation showing that RGBP is paying the Ichims salary in shares and not from the $775,000 in cash they raised. If they were paying salaries in shares wouldn't that be in the SEC filings of increased shares each filing period?
Dmort, to buy back shares you will need an excess of funds in order to spend some of it buying back the shares, while if you do the reverse split to reduce shares and raise the trading price, you could then either send a more limited and reasonable amount of shares under new structure to raise the necessary funds from true investment companies without diluting the share structure too much.
Many investment firms willing to buy shares at $5 that would not buy shares at .0005, .005 .05 or even .50.
Having a hard time making sense out of this. A R/S of stock does not change the value of your holdings nor of Koos'. The exercise of a stock split or a stock reverse split does not make income for anyone, it just changes the share structure and the price the stock trades at.
Seems a common comment here that a Reverse Split for a stock is a death knell and bad news. But how alive is a company's shares that cannot be traded because they trade at .0005? They are in the land of MMs on OTC pink.
I would welcome the following scenario: after RGBP submits HemaX data for final FDA approval and submits either a new IND or a material positive update on the dCellVax testing under Dr. Kesari, Koos then announces a Reverse Split of 10,000 to 1 to put BMSN at 5.00 and reduce the O/S to 300,000 and allow investment companies to get a piece of BMSN. RGBP will eventually go over $1.00 and allow for investment companies to come on board, so no need to R/S.
What is the negative in doing a R/S to allow investment companies to get involved after good and significant news?
The "dilution" factor in the PR regarding licensing fees being paid in cash or shares is nothing new. Koos licensed Benitec's IP when BMSN existed and RGBP did not. Now RGBP exists and the Benitec IP is being used in RGBP's development.
Therefore, the contract was amended so that the original terms of the Benitec-BMSN contract are passed on to RGBP as of April 2015. Makes sense and is not a new issue of dilution, but a material change to a material contract.
If a person didn't know about the licensing before, he should have and if he did, the change of the contract to follow the IP payments to the entity using it is logical and necessary.
Definitely would make sense and be good news as it would also not shed any negative light on BMSN selling RGBP shares other than for contractual payments.
This would be a plus and a winning situation as BMSN and RGBP only have to pay Benitec for milestone payments and each milestone reached will up the PPS of RGBP and BMSN.
Makes sense, let's hope it's true.
That would be great news if BMSN still owns 29M of RGBP and might be reason that there was buying of BMSN .0004s in afternoon in light of RGBP's progress. I'm hopeful as I still own some BMSN.
But the PR also states that BMSN and/or RGBP can issue more shares if needed to pay Benitec, so how would you "reconcile" this statement in the PR with your theory of the 70K being in "paid for" existing shares?
Also interesting to note that this news was held until today when it was executed on August 1st.
Sid, regarding your post below, the board has already hosted multiple comments and in depth explanations on the past. As you know, it wasn't until January 2015, that RGBP hired full time scientists as employees in order to be able to progress the research in a more orderly and assured manner.
The differences of past years compared to developments in 2015 are staggering for anyone willing to see things with an objective, unsullied eye. You can be critical of Koos and company decisions. I'm okay with that. But the constant barrage of projecting the future based on the past without any consideration for the developments that have occurred in the past year holds no more weight that the constant banter of "to the moon.
Sid, would you care to comment today and update your vision:
More importantly, it's not following the market down today. Low volume each day until mid-Sept won't bother me. The less people buy in today before news, the greater chance they will want to buy in when news comes out and therefore will provide more upward pressure when the news comes out.
Well, nice to see there's no panic sell off here. Each day that goes by and we get closer to CRL full report on HemaX, our chances of upward pressure should increase.
So nice to see no big downward activity here on a stock market sell off.
True. The news that BMSN sold shares of RGBP really didn't make any sense to me at all when I first read it. Since it doesn't help BMSN as a company to sell its stake in RGBP (where it has put all its IP and investment, outside of recent Zander developments), I was at a loss to understand.
Since we know Koos likes to position himself well in all transactions, it may be that he sold them to himself or himself and fellow "angel investors" as an added bonus in return for other favors. That's about the only angle that would seem to make sense...i.e. where he continues to benefit and maybe in a very big way from the sale of those shares.
Would be nice to know how many shares sold and to whom.
On the optimistic side, we are 20 trading days or less from the release of the full audited CRL report on HemaX which we expect to be positive (no indication it would be otherwise) and then only another 20 or so trading days until FDA approval followed by official Orphan Drug Status for HemaX.
With CRL doing the experiments, we don't have the worry of further delays or the experiments not being done right and with Dr. Kesari pursuing the dCellVax issues and experimental data, we won't have to wait another 2 years for dCellVax to move forward.
Success breeds success and as long as Koos allows the company to gain in value outside of himself, we should also benefit for our long term investments.
Unless Koos sold them to himself instead of giving BMSN a loan for his ongoing salary.
The fact they were sold is not good news for BMSN, but it is not necessarily related to bad news for RGBP. If BMSN sold all its shares in RGBP, then it is pretty much a death nell and totally insults investors in BMSN and gives more credence to those saying all the manuevers are just Koos playing games with people for his own profit.
If only a small portion of RGBP common shares were sold and BMSN still has a good stack of RGBP along with some preferred RGBP (I forget all the PRs in this regard), then we are okay in all senses and if Zander can take what RGBP is developing for humans and apply it to animals, BMSN will also benefit while Koos expands his salary by paying himself to lead Zander as well.
Laddyman, the link you sent regarding T. Ichim dates back to 2013. RGBP bought some or all of T. Ichim's IP when they hired him as an employee in 2015, so I believe what the video was referring to is now RGBP IP.
So in that regard, not an issue. The company has "a" webpage and no info and most likely consisted of T. Ichim and his IP research that he did with previous company before it was sold. His goal was to find a partner to pursue the IP and I think that partner is RGBP.
Back from some time away. I see not much has changed PPS even with progress on dCellVax announcement.
BMSN filed 10-Q on August 11th and this line caught my attention in shock:
Appears the previous link to Spain patent office is referring to the July 23, 2015 publication date of the patent C. Ichim filed in December 2014 for the treatment of NR2F6
Image of Patent pub
Thanks for posting. Patent for NR2F6 is very exciting indeed. The creation of Zander for animals to treat cancer using cell differentiation, the fact that the RGBP website recently updated mentions 7 hits for their proprietary process of identifying candidates for cell differentiation and now this international patent showing up with a date of 7/23/2015 means we could be in for some very significant news indeed.
One can only dream that they have found a compound and method that may work both in animals and humans to treat cancer via cell differentiation. It would be a definite game changer indeed.
As I've been saying 2015 is the year of hope for RGBP.
Go Ichims!
New month. Wouldn't be surprised to see an update tomorrow on developments other than HemaX as the beginning of the month is time for new money to be invested.
Would certainly help the company to build momentum if we can have material updates on products outside the CRL safety testing process.
I'm hopeful that the next couple of months will bring significant changes.